Biologics CDMO AsymBio to secure $184m from Asymchem Group, Hillhouse Qirui and other investors to support manufacturing growth
The funding, approximately 1.2397 billion yuan, will be used for AsymBio's principal business operations, further expansion of its manufacturing capacity, and scaling of client programs. Following the transaction, Asymchem Group's shareholding in its subsidiary AsymBio is set to rise to 83.4965%.
Source:Yahoo财经 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
DIA Coin: A Deep Dive into the Web3 Decentralized Data Oracle Platform and its Future Outlook
-
2
DOS Network (DOS) Project Analysis: Current Status and Future Outlook of Decentralized Oracles
-
3
BIXCPRO Token Analysis: Ethereum on-chain Asset Overview and Investment Risk Warning
-
4
Ethereum ERC-20 Token Standard: Definition, Function, and Ecosystem Impact
-
5
What is Phala Network (PHA)? Deconstructing its Decentralized Confidential AI Cloud and Token Utility
-
6
What is ZBK (Zbank Token)? Is it still tradable?
-
7
4-Way Mirror Money (4WMM) Token Analysis: A Reflective Cryptocurrency in the PulseChain Ecosystem and Its Potential Risks
-
8
The Evolution and Challenges of Ethereum: Dencun Upgrade, Vitalik's Vision, and Market Competition Analysis
-
9
Bitcoin's 30-day implied volatility index (BVIV) drops to 36%, its lowest since May 31, despite weak institutional demand and stablecoin market cap declines.
-
10
Bitcoin Storage Guide: Cold and Hot Wallet Choices and Security Practices
Markets Today
Recommended Reading











